Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 11/9/2025

Colchicine-Tacrolimus-Myfortic Drug Interaction Guidelines

Critical Interaction: Colchicine and Tacrolimus

  • The American Heart Association recommends reducing colchicine doses by 50-75% for prophylaxis and 33-66% for acute gout treatment when combined with tacrolimus due to life-threatening toxicity risk 1, 2
  • Colchicine undergoes hepatic demethylation by CYP3A4 and is a substrate for P-gp, making it highly vulnerable to accumulation when combined with tacrolimus, a moderate CYP3A4 inhibitor 1, 2
  • The American College of Cardiology suggests monitoring for early gastrointestinal symptoms, such as diarrhea, abdominal cramping, and vomiting, as the first warning signs of toxicity when using colchicine with tacrolimus 1

Tacrolimus and Myfortic (Mycophenolic Acid) Interaction

  • The American Society of Transplantation recommends monitoring for MPA-associated adverse reactions, including bone marrow suppression, gastritis, nausea, diarrhea, and abdominal pain, when tacrolimus is prescribed with mycophenolic acid (MPA) 3
  • The National Kidney Foundation suggests reducing the dose of mycophenolic acid products as needed based on clinical tolerance due to the unidirectional interaction where tacrolimus increases MPA levels 3